177 related articles for article (PubMed ID: 30396811)
1. Immunocorrelates of CAF family adjuvants.
Pedersen GK; Andersen P; Christensen D
Semin Immunol; 2018 Oct; 39():4-13. PubMed ID: 30396811
[TBL] [Abstract][Full Text] [Related]
2. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
[TBL] [Abstract][Full Text] [Related]
4. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
Del Giudice G; Rappuoli R; Didierlaurent AM
Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
[TBL] [Abstract][Full Text] [Related]
5. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
6. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
Ashhurst AS; Parumasivam T; Chan JGY; Lin LCW; Flórido M; West NP; Chan HK; Britton WJ
PLoS One; 2018; 13(3):e0194620. PubMed ID: 29554138
[TBL] [Abstract][Full Text] [Related]
7. Liposome-based cationic adjuvant formulations (CAF): past, present, and future.
Christensen D; Agger EM; Andreasen LV; Kirby D; Andersen P; Perrie Y
J Liposome Res; 2009; 19(1):2-11. PubMed ID: 19515003
[TBL] [Abstract][Full Text] [Related]
8. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
9. Correlates of GLA family adjuvants' activities.
Reed SG; Carter D; Casper C; Duthie MS; Fox CB
Semin Immunol; 2018 Oct; 39():22-29. PubMed ID: 30366662
[TBL] [Abstract][Full Text] [Related]
10. Adenylate kinase: a novel antigen for immunodiagnosis and subunit vaccine against tuberculosis.
Xiao Y; Sha W; Tian Z; Chen Y; Ji P; Sun Q; Wang H; Wang S; Fang Y; Wen HL; Zhao HM; Lu J; Xiao H; Fan XY; Shen H; Wang Y
J Mol Med (Berl); 2016 Jul; 94(7):823-34. PubMed ID: 26903285
[TBL] [Abstract][Full Text] [Related]
11. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
[TBL] [Abstract][Full Text] [Related]
12. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
[TBL] [Abstract][Full Text] [Related]
13. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
Henriksen-Lacey M; Devitt A; Perrie Y
J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
[TBL] [Abstract][Full Text] [Related]
14. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
15. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
[TBL] [Abstract][Full Text] [Related]
17. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
[TBL] [Abstract][Full Text] [Related]
18. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
20. New adjuvants in evolving vaccine strategies.
Buonaguro FM; Tornesello ML; Buonaguro L
Expert Opin Biol Ther; 2011 Jul; 11(7):827-32. PubMed ID: 21609186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
